Arrowhead Pharmaceuticals, Inc. (ARWR) Investor Relations Documents

Arrowhead Pharmaceuticals, Inc. (ARWR) investor relations documents from the company's IR site: 11 presentations, 29 press releases; latest deck 2026-06-29. Read in-app with summaries. First-party data.

View Presentation: Arrowhead Pharmaceuticals June 2026 Cardiometabolic R&D webinar detailing clinical progress for plozasiran, zodasiran, and the ARO-DIMER-PA pipeline candidate.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-04Press releaseArrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results
2026-08-04Press releaseArrowhead Pharmaceuticals Acquires FDA Priority Review Voucher
2026-08-03Press releaseArrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2026-07-22Press releaseArrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients w
2026-07-21Press releaseArrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results
2026-06-29PresentationView Presentation
2026-06-22Press releaseArrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Tr
2026-06-18Press releaseArrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&amp
2026-06-02Press releaseArrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events
2026-05-27Press releaseArrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026
2026-05-12PresentationView Presentation
Press releaseArrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results
Press releaseArrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results
2025-12-08PresentationView Presentation
2025-12-07PresentationCorporate Presentation - December 2025
2025-11-25Press releaseArrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results
2025-09-17PresentationView Presentation
2025-09-10PresentationView Presentation
Press releaseArrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results
Press releaseArrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results
2025-05-12PresentationATS 2025 RAGE Preclinical 1
2025-05-06PresentationECO2025 ALK7
2025-05-06PresentationATS 2025 IL33-TSLP
2025-05-01PresentationTIDES USA 2025 CNS
2025-03-06PresentationView Presentation
Press releaseArrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results
Press releaseArrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results
Press releaseArrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results
Press releaseArrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results
Press releaseArrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results
Press releaseArrowhead Pharmaceuticals Reports Fiscal 2023 Year End Results
Press releaseArrowhead Pharmaceuticals Reports Fiscal 2023 Third Quarter Results
Press releaseArrowhead Pharmaceuticals Reports Fiscal 2023 Second Quarter Results
Press releaseArrowhead Pharmaceuticals Reports Fiscal 2023 First Quarter Results
Press releaseArrowhead Pharmaceuticals Reports Fiscal 2022 Year End Results
Press releaseArrowhead Pharmaceuticals Reports Fiscal 2022 Third Quarter Results
Press releaseArrowhead Pharmaceuticals Reports Fiscal 2022 Second Quarter Results
Press releaseArrowhead Pharmaceuticals Reports Fiscal 2022 First Quarter Results
Press releaseArrowhead Pharmaceuticals Reports Fiscal 2021 Year End Results
Press releaseArrowhead Pharmaceuticals Reports Fiscal 2021 Third Quarter Results

ARWR overview · ARWR earnings · ARWR financials · ARWR KPIs · ARWR documents · ARWR ownership · ARWR peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.